Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma to Present at the 8th Annual SVB Leerink Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) diseases, today ...
View HTML
Toggle Summary RedHill Biopharma Announces Fifth U.S. Patent Covering TALICIA® for H. pylori Infection
Notice of Allowance received and, once granted, the new U.S. patent is expected to be valid until 2034 NDA submission is expected in H1/2019, with eligibility for 6-month priority review; Subject to FDA approval, U.S. commercial launch with RedHill’s existing sales force is planned for ...
View HTML
Toggle Summary RedHill Biopharma Announces Closing of $20 Million Underwritten Offering
TEL-AVIV, Israel and RALEIGH, N.C. , Dec. 11, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced the ...
View HTML
Toggle Summary RedHill Biopharma Announces Pricing of $20 Million Underwritten Offering
TEL-AVIV, Israel and RALEIGH, N.C. , Dec. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced the ...
View HTML
Toggle Summary RedHill Biopharma Announces Proposed Public Offering of its American Depositary Shares
TEL-AVIV, Israel and RALEIGH, N.C. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
View HTML
Toggle Summary RedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA® for H. pylori Infection
The ERADICATE Hp2 confirmatory Phase 3 study successfully met its primary endpoint of H. pylori eradication (84% vs. 58%) with high degree of statistical significance (p ...
View HTML
Toggle Summary RedHill Biopharma to Present at BMO 2018 Prescriptions for Success Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
View HTML
Toggle Summary RedHill Biopharma Announces Presentation on YELIVA® (opaganib) for Multiple Myeloma at EORTC-NCI-AACR Symposium
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases and cancer, today ...
View HTML
Toggle Summary RedHill Biopharma Reports Third Quarter 2018 Financial Results and Business Highlights
Key Highlights: Top-line results from the confirmatory Phase III study with TALICIA ® for H. pylori infection are on track to be announced by year-end 2018, with potential NDA filing in early 2019 Positive top-line results from the Phase III study with RHB-104 for Crohn’s disease - the study ...
View HTML
Toggle Summary RedHill Biopharma to Host Third Quarter 2018 Financial Results Conference Call on November 13, 2018
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
View HTML